Navigation Links
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Date:10/24/2007

COLLEGEVILLE, Pa., Oct. 24 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's supplemental New Drug Application (sNDA) for its first-in-class antibiotic Tygacil(R) (tigecycline) for the treatment of patients with community-acquired pneumonia (CAP). The FDA now will complete its review of the application. The FDA may approve or disapprove the application, request additional data or take other administrative actions.

"CAP is a serious respiratory disease that affects millions of Americans," says Gary L. Stiles, M.D., Executive Vice President, Chief Medical Officer, Wyeth Pharmaceuticals. "The acceptance of this sNDA is an important event as it brings Wyeth closer to providing physicians with a new option for the treatment of CAP."

The sNDA submission included integrated data from two investigational clinical studies that included 846 patients. Study data showed that Tygacil cured 89.7 percent of patients hospitalized with CAP, and levofloxacin - an existing treatment option for CAP - cured 86.3 percent of studied patients. The most common adverse events for Tygacil were nausea (24.3 percent), vomiting (16.0 percent) and abdominal pain (5.7 percent). The discontinuation rates due to adverse events for Tygacil and levofloxacin were similar (6.1 percent and 8.3 percent, respectively).

"As antibiotic resistance continues to be a concern for many strains of the most common bacteria causing CAP, there is a growing need for new options," says Thomas File, M.D., Chief of Infectious Disease Services for Summa Health System in Akron, Ohio.

About Community-Acquired Pneumonia'/>"/>

SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. American Society of Clinical Oncology (ASCO) Accepts New Data on AVR118 for Publication in 2007 Abstract Book
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. New Quality Control Systems for Every Laboratory Application
4. Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented
5. Antares Pharma Announces Positive Results from Application Site Study for Anturol
6. Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR
7. Point of Care Strep Tests Speed Treatment, Lower Costs
8. Rapid HIV Testing Increases Possibility of Treatment
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Novastem, a leader ... first patient in its study for ischemic stroke ... Stroke Association, ischemic strokes account for 87 percent ... qualified patients in the study, entitled "Internal Research ... Allogeneic Mesenchymal Stem Cells and Intrathecal Administration of ...
(Date:12/24/2014)... Dec. 24, 2014 Soligenix, Inc. (OTCQB: ... company developing products that address unmet medical needs ... announced today that on December 24, 2014 it ... The Company raised approximately $2.3 million in ... use the net proceeds from the offering to ...
(Date:12/24/2014)... NEW YORK and LONDON ... in global orthopedic industry are expected to grow at ... consumption in terms of value and volume. Hip, knee ... the developed world while in emerging economies they have ... failure rates are challenging the use of composites. Non-metallic ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3
... 27, 2011 JHP Pharmaceuticals, a leading ... announced today that it has entered into a multi-year ... of veterinary pharmaceutical products. JHP will be responsible for ... Jean Hoffman, CEO and founder of Putney said, ...
... Jan. 27, 2011 Following the acquisition of ... Heilbronn (" Future Fund of Heilbronn") the company ... (Heilbronn, Germany), which is expected to strengthen both medical ... (zfhn) announced that it has acquired Medos Medizintechnik AG ...
Cached Medicine Technology:JHP Pharmaceuticals and Putney Inc. Announce Multi-Year Contract Manufacturing Agreement 2Novalung and Medos Start Cooperation 2Novalung and Medos Start Cooperation 3Novalung and Medos Start Cooperation 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... The following is a,statement from Matthew L. Myers, ... and Ohio legislators have abandoned Ohio,s kids,and put the ... to,raid funds from the Ohio Tobacco Prevention Foundation. This ... children will become addicted to,tobacco, more Ohio citizens will ...
... April 8, 2008 The Center,for Connected ... of the,nation,s leading integrated health care delivery ... studies conducted at Partners-affiliated,hospitals, including Massachusetts General ... of connected health technologies.,These study findings, presented ...
... to two botanical functional ... ingredients, GLPH-1(TM) and PPL-240(TM), BIG HORN, Wyo., April ... validated and organically derived,ingredients for use in foods and ... GLPH-1(TM), an immune booster, and,PPL-240(TM), a photoprotective antioxidant, at ...
... output, breathing improve, researchers say , , TUESDAY, April 8 ... is enough to boost the cardiac performance and breathing ... finds. , This slightly more strenuous exercise program -- ... failure -- works at least as well as the ...
... What do you learn by looking at the spines of ... of researchers behind the Twin Spine Study, you find compelling ... of genetics than physical strain. , The findings of the ... have led to a dramatic paradigm shift in the way ...
... in the developing world is the litany of tropical ... by the public health community. This is the ... published by ASM Press. , Some of the worst ... ignored. Parasitic and bacterial diseases such as hookworm, ...
Cached Medicine News:Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 2Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 3Health News:Center for Connected Health Presents Growing Evidence of the Benefits of Technology to Improve Patient Satisfaction and Empowerment 4Health News:Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008 2Health News:Gourmetceuticals Presents Findings on Science You Can Eat at Experimental Biology 2008 3Health News:A Month of Exercise Helps Ease Heart Failure 2Health News:Award-winning study says back pain may be in your genes 2Health News:Forgotten diseases key to lifting developing world from poverty, destitution and despair 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: